Scientists from the University of Oxford, the Francis Crick Institute and University College London (UCL) have used technology similar to the Oxford-AstraZeneca COVID-19 vaccine to create the "LungVax," a vaccine which activates the immune system to kill cancer cells and stop lung cancer.
The team has been granted up to £1.7m in funding by charities, Cancer Research UK and the CRIS Cancer Foundation, to manufacture 3,000 doses of the vaccine. It works by using a strand of DNA which trains the immune system to recognise "red flag" proteins in lung cancer cells - known as neoantigens - and kill them.